Srinivas Akkaraju, Director, 10% Owner at Kalaris Therapeutics, Inc. (KLRS), bought 244,300 shares at $4.83 ($1.2M) on 2026-05-20, disclosed to the SEC on 2026-05-22.
Director Srinivas Akkaraju purchased 244,300 shares for $1.18M, marking the largest insider purchase in the company's history. This significant capital commitment suggests the insider believes the stock is undervalued following a steep 50.7% decline over the last 90 days.
The stock is currently trading at $4.93, down 50.7% over the last 90 days and 22.12% over the last 30 days, though it remains 9.07% above its 52-week low of $4.52.
Largest insider purchase in company history on May 20, 2026, signaling high conviction in the current valuation.
The stock carries a high short interest of 10.71%, which could exacerbate volatility if the price fails to sustain momentum. Additionally, the company is trading at a negative forward P/E of -3.11, indicating ongoing losses that may pressure the stock if cash burn accelerates.
Clearly above the average filing.
| Filing → |
| ALMS | BUY | 2026-01-13 | $10.0M | — | Filing → |
| SRRK | BUY | 2025-12-16 | $1.9M | — | Filing → |
| ALMS | BUY | 2025-12-09 | $3.7M | — | Filing → |